177 related articles for article (PubMed ID: 20028330)
1. Emerging antiviral drugs for hepatitis C virus.
Enomoto M; Tamori A; Kawada N
Rev Recent Clin Trials; 2009 Sep; 4(3):179-84. PubMed ID: 20028330
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus virology and new treatment targets.
Meier V; Ramadori G
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
[TBL] [Abstract][Full Text] [Related]
3. New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.
Tong J; Wang YW; Lu YA
J Zhejiang Univ Sci B; 2012 Jan; 13(1):56-82. PubMed ID: 22205621
[TBL] [Abstract][Full Text] [Related]
4. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
Welsch C; Jesudian A; Zeuzem S; Jacobson I
Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
[TBL] [Abstract][Full Text] [Related]
5. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
Kanda T; Nakamoto S; Sasaki R; Nakamura M; Yasui S; Haga Y; Ogasawara S; Tawada A; Arai M; Mikami S; Imazeki F; Yokosuka O
Int J Med Sci; 2016; 13(4):310-5. PubMed ID: 27076789
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for hepatitis C.
Soriano V; Madejon A; Vispo E; Labarga P; Garcia-Samaniego J; Martin-Carbonero L; Sheldon J; Bottecchia M; Tuma P; Barreiro P
Expert Opin Emerg Drugs; 2008 Mar; 13(1):1-19. PubMed ID: 18321145
[TBL] [Abstract][Full Text] [Related]
7. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.
Lenz O; Verbinnen T; Fevery B; Tambuyzer L; Vijgen L; Peeters M; Buelens A; Ceulemans H; Beumont M; Picchio G; De Meyer S
J Hepatol; 2015 May; 62(5):1008-14. PubMed ID: 25445400
[TBL] [Abstract][Full Text] [Related]
8. New HCV therapies on the horizon.
Vermehren J; Sarrazin C
Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
[TBL] [Abstract][Full Text] [Related]
9. Antiviral resistance and specifically targeted therapy for HCV (STAT-C).
Thompson AJ; McHutchison JG
J Viral Hepat; 2009 Jun; 16(6):377-87. PubMed ID: 19472445
[TBL] [Abstract][Full Text] [Related]
10. Viral determinants of resistance to treatment in patients with hepatitis C.
Wohnsland A; Hofmann WP; Sarrazin C
Clin Microbiol Rev; 2007 Jan; 20(1):23-38. PubMed ID: 17223621
[TBL] [Abstract][Full Text] [Related]
11. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
Zoulim F; Moreno C; Lee SS; Buggisch P; Horban A; Lawitz E; Corbett C; Lenz O; Fevery B; Verbinnen T; Shukla U; Jessner W
Virol J; 2018 Jan; 15(1):26. PubMed ID: 29378602
[TBL] [Abstract][Full Text] [Related]
12. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
Lin C; Kwong AD; Perni RB
Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
[TBL] [Abstract][Full Text] [Related]
13. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
14. Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
Klibanov OM; Williams SH; Smith LS; Olin JL; Vickery SB
Pharmacotherapy; 2011 Oct; 31(10):951-74. PubMed ID: 21950642
[TBL] [Abstract][Full Text] [Related]
15. Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
Wyles DL
J Infect Dis; 2013 Mar; 207 Suppl 1():S33-9. PubMed ID: 23390303
[TBL] [Abstract][Full Text] [Related]
16. Development of novel treatments for hepatitis C.
Webster DP; Klenerman P; Collier J; Jeffery KJ
Lancet Infect Dis; 2009 Feb; 9(2):108-17. PubMed ID: 19179226
[TBL] [Abstract][Full Text] [Related]
17. Preliminary study of two antiviral agents for hepatitis C genotype 1.
Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
19. New developments in HCV therapy.
Kronenberger B; Zeuzem S
J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
[TBL] [Abstract][Full Text] [Related]
20. Investigational drugs for hepatitis C.
Flisiak R; Parfieniuk A
Expert Opin Investig Drugs; 2010 Jan; 19(1):63-75. PubMed ID: 20001555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
